[go: up one dir, main page]

NO2023043I1 - Mavacamten or a pharmaceutically acceptable salt thereof - Google Patents

Mavacamten or a pharmaceutically acceptable salt thereof

Info

Publication number
NO2023043I1
NO2023043I1 NO2023043C NO2023043C NO2023043I1 NO 2023043 I1 NO2023043 I1 NO 2023043I1 NO 2023043 C NO2023043 C NO 2023043C NO 2023043 C NO2023043 C NO 2023043C NO 2023043 I1 NO2023043 I1 NO 2023043I1
Authority
NO
Norway
Prior art keywords
mavacamten
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NO2023043C
Other languages
English (en)
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51177189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2023043(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of NO2023043I1 publication Critical patent/NO2023043I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO2023043C 2013-06-21 2023-12-01 Mavacamten or a pharmaceutically acceptable salt thereof NO2023043I1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838088P 2013-06-21 2013-06-21
US201461939655P 2014-02-13 2014-02-13
US201461981366P 2014-04-18 2014-04-18

Publications (1)

Publication Number Publication Date
NO2023043I1 true NO2023043I1 (no) 2023-12-01

Family

ID=51177189

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2023043C NO2023043I1 (no) 2013-06-21 2023-12-01 Mavacamten or a pharmaceutically acceptable salt thereof

Country Status (39)

Country Link
US (9) US9181200B2 (no)
EP (2) EP3010910B1 (no)
JP (4) JP6603213B2 (no)
KR (4) KR20230144117A (no)
CN (2) CN109384729B (no)
AU (5) AU2014281408B2 (no)
BR (1) BR112015031864B1 (no)
CA (1) CA2915967C (no)
CL (1) CL2015003689A1 (no)
CR (1) CR20160032A (no)
CY (2) CY1122964T1 (no)
DK (1) DK3010910T3 (no)
DO (1) DOP2015000300A (no)
EA (2) EA030846B1 (no)
ES (1) ES2773250T3 (no)
FI (1) FIC20230036I1 (no)
FR (1) FR23C1047I2 (no)
GT (1) GT201500348A (no)
HK (1) HK1223930A1 (no)
HR (1) HRP20200379T1 (no)
HU (2) HUE047566T2 (no)
IL (6) IL302299A (no)
LT (1) LT3010910T (no)
MX (3) MX2021005326A (no)
MY (1) MY190860A (no)
NL (1) NL301253I2 (no)
NO (1) NO2023043I1 (no)
PE (1) PE20160208A1 (no)
PH (2) PH12021552715A1 (no)
PL (1) PL3010910T3 (no)
PT (1) PT3010910T (no)
RS (1) RS59906B1 (no)
SG (2) SG10201803459TA (no)
SI (1) SI3010910T1 (no)
SM (1) SMT202000071T1 (no)
TN (1) TN2015000553A1 (no)
UA (1) UA117929C2 (no)
WO (1) WO2014205223A1 (no)
ZA (1) ZA201508959B (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011349578B2 (en) 2010-12-23 2016-06-30 Twelve, Inc. System for mitral valve repair and replacement
EP3964176A1 (en) 2011-06-21 2022-03-09 Twelve, Inc. Prosthetic heart valve devices
EA201400478A1 (ru) 2011-10-19 2014-10-30 Твелв, Инк. Устройства, системы и способы протезирования сердечного клапана
US9039757B2 (en) 2011-10-19 2015-05-26 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
WO2013059747A1 (en) 2011-10-19 2013-04-25 Foundry Newco Xii, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US11202704B2 (en) 2011-10-19 2021-12-21 Twelve, Inc. Prosthetic heart valve devices, prosthetic mitral valves and associated systems and methods
US9579198B2 (en) 2012-03-01 2017-02-28 Twelve, Inc. Hydraulic delivery systems for prosthetic heart valve devices and associated methods
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
ES2901711T3 (es) 2014-02-13 2022-03-23 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
CA2939081C (en) 2014-02-13 2023-08-15 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
PH12017501817B1 (en) 2015-04-03 2023-06-16 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
TWI765860B (zh) 2015-08-12 2022-06-01 美商英塞特公司 Lsd1抑制劑之鹽
CN106432222A (zh) * 2016-09-19 2017-02-22 丹诺医药(苏州）有限公司 8‑氯‑1‑环丙基‑7‑氟‑9‑甲基‑4‑氧‑4‑氢‑喹嗪‑3‑羧酸酯及其制备方法
CN106946851B (zh) * 2017-03-14 2019-11-12 牡丹江医学院 一种用于预防和治疗肾结石的药物
US10575950B2 (en) 2017-04-18 2020-03-03 Twelve, Inc. Hydraulic systems for delivering prosthetic heart valve devices and associated methods
US10646338B2 (en) 2017-06-02 2020-05-12 Twelve, Inc. Delivery systems with telescoping capsules for deploying prosthetic heart valve devices and associated methods
EP3661514A1 (en) * 2017-08-04 2020-06-10 Myokardia, Inc. Mavacamten for use in the treatment of hypertrophic cardiomyopathy
TW202436291A (zh) 2018-01-19 2024-09-16 美商胞質動力學公司 心肌節抑制劑
EP3814342B1 (en) 2018-06-26 2022-07-27 Cytokinetics, Inc. Cardiac sarcomere inhibitors
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3110237A1 (en) * 2018-08-31 2020-03-05 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7447110B2 (ja) * 2018-10-29 2024-03-11 マイオカーディア，インク テトラヒドロピラン（ｔｈｐ）－置換二環式－ピリミジンジオン化合物
WO2020151605A1 (zh) * 2019-01-25 2020-07-30 青岛吉澳医药科技有限公司 氘代苯甲氨嘧啶二酮衍生物及其用途
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
BR112022008641A2 (pt) * 2019-11-10 2022-09-13 Myokardia Inc Métodos de tratamento com modulador de miosina
EP4097091B1 (en) * 2020-01-28 2024-09-18 Assia Chemical Industries Ltd. Solid state forms of mavacamten and process for preparation thereof
WO2022047004A1 (en) 2020-08-28 2022-03-03 MyoKardia, Inc. Methods of treatment with myosin modulator
AU2021381664A1 (en) 2020-11-20 2023-06-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
WO2022111498A1 (zh) * 2020-11-24 2022-06-02 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) * 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
US20240082248A1 (en) * 2021-02-01 2024-03-14 Dr. Reddy's Laboratories Limited Process for preparation of mavacamten and solid state forms thereof
IL305628A (en) 2021-03-04 2023-11-01 Cytokinetics Inc Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
TW202302541A (zh) * 2021-03-17 2023-01-16 美商翰森生物有限責任公司 含氮雜環酮、其製備方法和醫藥用途
EP4371978A1 (en) * 2021-07-13 2024-05-22 Nippon Soda Co., Ltd. Method for producing uracil compound
JP7315632B2 (ja) * 2021-09-16 2023-07-26 楽天グループ株式会社 特典付与システム、特典付与方法、及びプログラム
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
WO2023199258A1 (en) 2022-04-13 2023-10-19 Teva Pharmaceuticals International Gmbh Solid state forms of mavacamten and process for preparation thereof
WO2023211872A1 (en) 2022-04-26 2023-11-02 MyoKardia, Inc. Methods of administering myosin inhibitors
AU2023270440A1 (en) 2022-05-20 2024-12-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Crystal forms of triazine dione derivative and preparation method therefor
TW202416997A (zh) * 2022-09-16 2024-05-01 大陸商江蘇豪森藥業集團有限公司 一種含氮雜環酮化合物的晶型及其製備方法
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy
WO2024218783A1 (en) * 2023-04-17 2024-10-24 Dasha Pharmaceuticals Private Limited Green chemistry approach for synthesis of mavacamten and its intermediate using novel methodology
WO2025027567A1 (en) 2023-08-03 2025-02-06 Olon S.P.A. Process for preparing mavacamten and process intermediate
WO2025046606A1 (en) 2023-08-26 2025-03-06 Micro Labs Limited Granules of mavacamten for oral administration

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1280877B (de) 1960-11-16 1968-10-24 Robugen Gmbh Verfahren zur Herstellung von in 1-Stellung substituierten 4-Aminouracilen
JPS61205261A (ja) 1985-03-08 1986-09-11 Sagami Chem Res Center ６―置換―５―フルオロウラシル誘導体
JPH0637479B2 (ja) * 1987-12-28 1994-05-18 三井東圧化学株式会社 新規ピリミジン誘導体、その製造法およびそれを含有する抗不整脈剤
US5008267A (en) 1988-10-29 1991-04-16 Mitsui Toatsu Chemicals, Incorporated Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same
JPH03173885A (ja) 1989-12-01 1991-07-29 Mitsui Toatsu Chem Inc ピリミジンジオン誘導体化合物、該化合物の製造法および該化合物を含む抗不整脈剤
FR2659656B1 (fr) 1990-03-15 1994-09-09 Sanofi Sa Derives de pyrimidinedione-2,4 et medicaments les contenant.
JPH0413669A (ja) * 1990-04-27 1992-01-17 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体及び該化合物を含有する抗不整脈剤
JPH06128238A (ja) * 1992-10-20 1994-05-10 Mitsui Toatsu Chem Inc 新規ピリミジンジオン誘導体
EP0697407B1 (en) 1994-08-19 1997-06-25 MITSUI TOATSU CHEMICALS, Inc. Pyrimidinedione derivatives and antiarrhythmic compositions containing same
US5516905A (en) 1994-08-30 1996-05-14 University Of Massachusetts Medical Center Antibiotic compounds and methods to treat gram-positive bacterial and mycoplasmal infections
ES2189300T3 (es) 1998-06-26 2003-07-01 Crompton Vinyl Additives Gmbh Nuevos 6-aminouracilos modificados con nh2 como estabilizadores para polimeros halogenados.
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7416856B2 (en) 1999-05-18 2008-08-26 Cytokinetics, Inc. High sensitivity assay for detection of nucleoside diphosphate production
AU2247701A (en) 1999-10-21 2001-04-30 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
US20030114414A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi Methods for synthesizing substituted pyrimidines
US20030114445A1 (en) 2001-06-15 2003-06-19 Chengxin Zhi N3-substituted 6-anilinopyrimidines and methods to treat-Gram-positive bacterial and mycoplasmal infections
WO2002102769A2 (en) 2001-06-15 2002-12-27 University Of Massachusetts Methods for synthesizing substituted pyrimidines
DE10208460A1 (de) 2002-02-27 2003-09-04 Bayer Ag Uracil-Thioether
EP1553949B1 (en) * 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
CA2559302C (en) 2004-03-15 2012-06-19 Takeda Pharmaceutical Company Limited 6-amino-1h-pyrimidine-2,4-dione derivatives as dipeptidyl peptidase inhibitors
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
JP2011507910A (ja) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
GB0908193D0 (en) * 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
WO2014205234A1 (en) * 2013-06-21 2014-12-24 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
CA2915967C (en) 2021-07-20
US20240382486A1 (en) 2024-11-21
MX382520B (es) 2025-03-13
US20170281626A1 (en) 2017-10-05
IL275837A (en) 2020-08-31
CN109384729A (zh) 2019-02-26
MX2015017865A (es) 2016-09-06
USRE50050E1 (en) 2024-07-23
HUS2300042I1 (hu) 2024-01-28
PE20160208A1 (es) 2016-05-04
EA030846B1 (ru) 2018-10-31
MY190860A (en) 2022-05-12
CA2915967A1 (en) 2014-12-24
FR23C1047I1 (fr) 2024-01-12
MX2022014414A (es) 2022-12-07
NL301253I1 (no) 2023-12-13
BR112015031864A2 (pt) 2017-07-25
CN105473576B (zh) 2018-10-30
CL2015003689A1 (es) 2016-10-14
KR102359158B1 (ko) 2022-02-08
IL275837B (en) 2021-09-30
JP2020019809A (ja) 2020-02-06
PL3010910T3 (pl) 2020-07-27
PH12021552715A1 (en) 2022-05-11
HK1223930A1 (zh) 2017-08-11
EP3010910B1 (en) 2020-02-05
IL243222B (en) 2020-07-30
KR102304121B1 (ko) 2021-09-24
TN2015000553A1 (en) 2017-04-06
ZA201508959B (en) 2022-09-28
IL310829A (en) 2024-04-01
HRP20200379T1 (hr) 2020-06-12
IL243222A0 (en) 2016-02-29
KR20220020410A (ko) 2022-02-18
US9585883B2 (en) 2017-03-07
IL302299A (en) 2023-06-01
AU2014281408B2 (en) 2018-08-16
IL285971A (en) 2021-10-31
SI3010910T1 (sl) 2020-04-30
ES2773250T3 (es) 2020-07-10
EP3010910A1 (en) 2016-04-27
HUE047566T2 (hu) 2020-04-28
AU2020204271B2 (en) 2022-01-06
AU2014281408A1 (en) 2016-01-21
GT201500348A (es) 2018-12-20
EP3702352A1 (en) 2020-09-02
NL301253I2 (nl) 2024-01-10
SG10201803459TA (en) 2018-05-30
KR20160026997A (ko) 2016-03-09
KR20210118470A (ko) 2021-09-30
DOP2015000300A (es) 2016-03-15
DK3010910T3 (da) 2020-02-17
KR20230144117A (ko) 2023-10-13
US20210346379A1 (en) 2021-11-11
AU2024202464A1 (en) 2024-05-02
US9181200B2 (en) 2015-11-10
US20160030428A1 (en) 2016-02-04
NZ715456A (en) 2021-01-29
SG11201510163TA (en) 2016-01-28
CY2023027I2 (el) 2024-09-20
JP6980734B2 (ja) 2021-12-15
AU2020204271A1 (en) 2020-07-16
CY1122964T1 (el) 2021-10-29
PH12015502794B1 (en) 2022-09-02
RS59906B1 (sr) 2020-03-31
CY2023027I1 (el) 2024-02-16
US20200297726A1 (en) 2020-09-24
EA201891009A1 (ru) 2018-09-28
US20230165860A1 (en) 2023-06-01
JP2024010108A (ja) 2024-01-23
CR20160032A (es) 2016-04-01
AU2022202298A1 (en) 2022-04-28
BR112015031864B1 (pt) 2022-02-15
JP2016522263A (ja) 2016-07-28
SMT202000071T1 (it) 2020-03-13
AU2018264088A1 (en) 2018-12-06
IL317628A (en) 2025-02-01
PT3010910T (pt) 2020-02-21
JP2022036966A (ja) 2022-03-08
FIC20230036I1 (fi) 2023-12-01
PH12015502794A1 (en) 2016-03-21
MX2021005326A (es) 2022-11-17
CN109384729B (zh) 2023-06-30
WO2014205223A1 (en) 2014-12-24
JP6603213B2 (ja) 2019-11-06
US20180311242A1 (en) 2018-11-01
US20140378464A1 (en) 2014-12-25
FR23C1047I2 (fr) 2024-11-15
UA117929C2 (uk) 2018-10-25
EA201690066A1 (ru) 2016-05-31
JP7376556B2 (ja) 2023-11-08
CN105473576A (zh) 2016-04-06
LT3010910T (lt) 2020-03-10

Similar Documents

Publication Publication Date Title
NO2024042I1 (no) Iptacopan or a pharmaceutically acceptable salt thereof
NO2023043I1 (no) Mavacamten or a pharmaceutically acceptable salt thereof
NO2022005I1 (no) Zanubrutinib or a pharmaceutically acceptable salt thereof
NO2024001I1 (no) Ritlecitinib, or a pharmaceutically acceptable salt thereof
NO2022004I1 (no) abrocitinib, or a pharmaceutically acceptable salt thereof
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
NO2021035I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof
NL301094I2 (nl) Avapritinib en farmaceutisch aanvaardbare zouten daarvan
NO2022010I1 (no) ripretinib, or a pharmaceutically acceptable salt thereof
FIC20230028I1 (fi) Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
FIC20240030I1 (fi) Danikopaani tai sen farmaseuttisesti hyväksyttävä suola
FIC20240012I1 (fi) Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NO2020029I1 (no) Givosiran eller et farmasøytisk akseptabelt salt derav
NO2022058I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
HUE037275T2 (hu) Gyógyszer-kombináció
ZA201603624B (en) Urea derivative or pharmacologically acceptable salt thereof
DK2970389T3 (da) Farmaceutiske forbindelser
LT3077047T (lt) Aramcholio druskos
DE112014004161A5 (de) Rotationsrheometer
NO2024058I1 (no) delgocitinib or a pharmaceutically acceptable salt thereof
LT3079667T (lt) Farmacinės vaisto formos
BR302014001964S1 (pt) Configuração aplicada a travesseiro
DK3003401T3 (da) Farmaceutisk præparat
FR3010437B1 (fr) Serrure a mortaiser reglable